. Synthetic scheme for the Adamantane-BHQ2 conjugate. Figure S4 . Calibration curve of compound 3 in the presence of 100 nM and 1 μM of Adamantane-BHQ2. This curve is fitted using a Hill function on the measured data points. Because of the competitive binding nature, the fluorescence intensity depends on the concentration of the Adamantane-BHQ2. Figure S5 . (Left) Compound 3 decreases the glutamate concentration in the cell, indicating that the glutamine uptake is inhibited by compound 3. The glutamate concentration was measured using the aforementioned kit. Because compound 3 is not a preferred substrate for glutamine transporters, it requires large amount of it to induce the change in glutamate concentration. In this case, the cells were incubated with or without 4 mM of compound 3, in the presence of 1 mM glutamine. (Right) SLC1A5-knock down experiments using three different siRNA sequences. siRNA 1 was chosen for subsequent uptake experiments described in Fig 2. The information for involved siRNA is: siRNA 1 (ThermoFisher s12917, targeting NCBI NM_001145144.1, exons 2,3; location 97), siRNA 2 (ThermoFisher s12918, targeting NM_001145144.1, exon 5; location 371), and siRNA 3 (ThermoFisher s12917, targeting NM_001145144.1, exons 8; location 978). Figure S6 . The result of compound 3 uptake and glutamate assays. Cells were treated with different concentrations of erlotinib for 24 h and then assayed. The glutamate was measured using a commercial kit (Abcam, ab83389). The agreement between the two measurements proves that compound 3 is a good surrogate for glutamine. Figure S7 . The toxicity test of compound 3. The cells were treated with different concentrations of compound 3 for 48 h, and the cell numbers were normalized to the control sample. Compound 3 not only did not show any inhibition towards proliferation, but rather enhanced it. The mechanism to this observation is unknown. However, because in the real assay, cells are only incubated with compound 3 for 30 min, therefore it is reasonable to assume its negligible effect. Figure S8 . A) Illustration of the SCBC platform and typical images of the single cell chamber and the corresponding fluorescence barcode result. The cell is highlighted in the red circle. B) The methods for quantifying i) proteins, ii) cAMP/cGMP, iii) GSH and iv) glucose uptake. The protein detection is based on sandwich-type immunofluorescence assay and the metabolites are measured through surface competition fluorescence assays. [M. Xue, et al, J. Am. Chem. Soc., 137, 4066-4069 (2015) ] Figure S9 . The cell growth curve upon 1 μM and 10 μM of erlotinib treatment. It is obvious that 1 μM erlotinib cannot inhibit cell growth, while 10 μM is effectively slowing down the cell proliferation. where α is the multi-sample normalized activity coefficient, ranging (0,1) Figure S11 . Dendrogram of the clustering results on each SCBC data set.
